The groundbreaking success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but investing in companies strongly reliant on generic versions presents a challenging picture. While early returns were significant, the cessation of patents and the emergence of cheaper alternatives have diminished the customer base. Consequently, a t